Eritropoyesis ineficaz y su afección en la funcionalidad de la médula ósea en niños
Resumen
La anemia aplásica ha sido considerada una patología sanguínea poco frecuente que puede llegar a ser fatal en caso no tener los controles y tratamientos necesarios, está asociada con la falla de la funcionalidad de la medula ósea de origen autoinmune, estos síndromes de insuficiencia funcional suelen estar relacionados con infecciones virales y toxinas ambientales, además de mutaciones genéticas heredadas y adquiridas, y es gracias a esto que desencadenan en un desnivel de los recuentos sanguíneos normales, los cuales originan una disminución de la capacidad física y desarrollo normal de las actividades diarias del paciente, predominando su presentación en la población pediátrica. La patología tiene como principales tratamientos exitosos el trasplante de las células madre hematopoyéticas y la terapia inmunosupresora, los cuales mejoran la calidad de vida y supervivencia de los afectados, en los cuales este diagnóstico era prácticamente fatal en el pasado, pese a esto, se ha mantenido un constante estudio de otros posibles tratamientos sin haber tenido éxito en encontrar uno con una tasa de efectividad parecida a los mencionados.
Descargas
Citas
Young NS. Aplastic Anemia. N Engl J Med. 2018 25; 379(17):1643-56. DOI: 10.1056/NEJMra1413485.
Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013; 2013(1):76-81. DOI: 10.1182/asheducation-2013.1.76
Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018; 124(21):4192-4201. DOI: 10.1002/cncr.31658.
Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997; 336(19):1365-72. DOI: 10.1056/NEJM199705083361906.
Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004; 364(9431):355-64. DOI: 10.1016/S0140-6736(04)16724-X.
Zoumbos NC, Gascón P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985; 312(5):257-65. DOI: 10.1056/NEJM198501313120501.
Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, Et al. Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. J Immunol. 2016; 196(4):1568-78. DOI: 10.4049/jimmunol.1501739.
Liu CY, Fu R, Wang HQ, Li LJ, Liu H, Guan J, Et al. Fas/FasL in the immune pathogenesis of severe aplastic anemia. Genet Mol Res. 2014; 13(2):4083-8. DOI: 10.4238/2014.May.30.3.
Montané E, Ibáñez L, Vidal X, Ballarín E, Puig R, García N, Et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008; 93(4):518-23. DOI: 10.3324/haematol.12020.
Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood. 1987; 70(6):1718-21.
Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1990 15; 75(8):1646-53.
Contejean A, Resche-Rigon M, Tamburini J, Alcantara M, Jardin F, Lengliné E, Et al. Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2019; 104(2):256-62. DOI: 10.3324/haematol.2018.198440.
Tichelli A, Socié G, Henry-Amar M, Marsh J, Passweg J, Schrezenmeier H, Et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999; 130(3):193-201. DOI: 10.7326/0003-4819-130-3-199902020-00004.
Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005; 365(9471):1647-56. DOI: 10.1016/S0140-6736(05)66515-4.
Li SS, Hsu YT, Chang C, et al. Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019; 98(1):29–39. DOI: 10.1007/s00277-018-3486-3.
Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017; 102(10):1683–90. DOI: 10.3324/haematol.2017.169862.
Norasetthada L, Wongkhantee S, Chaipokam J, et al. Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study. Ann Hematol. 2021; 100(10):2443–52. DOI: 10.1007/s00277-021-04566-0
Wan Z, Chen M, Han B. Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial. Ann Med. 2023; 55(1):2224044. DOI: 10.1080/07853890.2023.2224044.
Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K, Et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000; 111(1):321-8. DOI: 10.1046/j.1365-2141.2000.02289.x.
Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, Et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000; 37(1):69-80. DOI:10.1016/s0037-1963(00)90031-3.
Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, Et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014; 99(12):1784-91. DOI: 10.3324/haematol.2014.109355.
Peslak SA, Olson T, Babushok DV. Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol. 2017; 18(12):70. DOI: 10.1007/s11864-017-0511-z.
Dufour C, Pillon M, Sociè G, Rovò A, Carraro E, Bacigalupo A, Et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015; 169(4):565-73. DOI: 10.1111/bjh.13297.
Goronkova O, Novichkova G, Salimova T, Kalinina I, Baidildina D, Petrova U, Et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Adv. 2023. 28; 7(6):953-62. DOI: 10.1182/bloodadvances.2021006716.
Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022; 386(1):11-23. DOI: 10.1056/NEJMoa2109965.
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11-9. DOI: 10.1056/NEJMoa1200931.
Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, Et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019; 6(11): 562-72. DOI: 10.1016/S2352-3026(19)30153-X.
Lino M, Jinguji A, Sato T, Nakadate A. Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution. Hematology. 2022; 27(1):360-66. DOI: 10.1080/16078454.2022.2045725.
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017; 376(16):1540–50. DOI: 10.1056/NEJMoa1613878.
Rush ET, Schaefer GB, Sanger WG, Coccia PF. Aplastic Anemia in Two Patients with Sex Chromosome Aneuploidies. Cytogenet Genome Res. 2015; 147(1):31-4. DOI: 10.1159/000441585.
Aldarwish M, Alaithan I, Alawami F. Aplastic Anemia in Triple X Syndrome. Children (Basel). 2023; 10(1):100. DOI: 10.3390/children10010100.
Urbanowicz I, Nahaczewska W, Celuch B. Narrative review of aplastic anemia-the importance of supportive treatment. Ann Palliat Med. 2021; 10(1):694-699. DOI: 10.21037/apm-20-1957.
Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018; 124(21):4192-4201. DOI: 10.1002/cncr.31658.
Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013; 122(14):2453-9. DOI: 10.1182/blood-2013-04-494930.
Narita A, Muramatsu H, Sekiya Y, Okuno Y, Sakaguchi H, Nishio N, et al. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. Haematologica. 2015; 100(12):1546-52. DOI: 10.3324/haematol.2015.132530.
Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012; 119(23):5391-6. DOI: 10.1182/blood-2012-02-407684.
Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009; 94(3):348-54. DOI: 10.3324/haematol.13829.
Young NS. Mouse medicine and human biology. Semin Hematol. 2013; 50(2):88-91. DOI: 10.1053/j.seminhematol.2013.03.024.
Calado RT, Graf SA, Wilkerson KL, Kajigaya S, Ancliff PJ, Dror Y,et al. Mutations in the SBDS gene in acquired aplastic anemia. Blood. 2007; 110(4):1141-6. DOI: 10.1182/blood-2007-03-080044.
Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-65. DOI: 10.1056/NEJMra0903373.
Calado RT, Cooper JN, Padilla-Nash HM, Sloand EM, Wu CO, et al. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia. 2012; 26(4):700-7. DOI: 10.1038/leu.2011.272.
Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975; 45(3):355-63.
Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988; 70(2):177-82. DOI: 10.1111/j.1365-2141.1988.tb02460.x.
Dokal I, Tummala H, Vulliamy T. Inherited bone marrow failure in the pediatric patient. Blood. 2022; 140(6):556-570. DOI: 10.1182/blood.2020006481.
Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2011; 2011:84-9. DOI: 10.1182/asheducation-2011.1.84.
Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. Pediatr Clin North Am. 2013; 60(6):1311-36. DOI: 10.1016/j.pcl.2013.08.011.
Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood. 2002; 100(1):178-83. DOI: 10.1182/blood-2002-01-0236
Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002; 100(4):1185-91. DOI: 10.1182/blood-2002-01-0035.
Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012; 119(9):2033-43. DOI: 10.1182/blood-2011-08-368308.
de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010; 116(20):4175-84. DOI: 10.1182/blood-2010-01-266098.
Imada K, Obara N, Iida H, Imajo K, Maeda T, Usuki K, et al. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan. Intern Med. 2021; 60(8):1159-1168. DOI: 10.2169/internalmedicine.6063-20.
Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014; 99(4):664-71. DOI: 10.3324/haematol.2013.089268.
Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015; 171(4):585-94. DOI: 10.1111/bjh.13614.
Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994; 330(4):249-55. DOI: 10.1056/NEJM199401273300404.
Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993; 259(5099):1318-20. DOI: 10.1126/science.7680492.
Tutelman PR, Aubert G, Milner RA, Dalal BI, Schultz KR, Deyell RJ. Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia. Br J Haematol. 2014; 164(5):717-21. DOI: 10.1111/bjh.12656.
Kulagin A, Lisukov I, Ivanova M, Golubovskaya I, Kruchkova I, Bondarenko S, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol. 2014; 164(4):546-54. DOI: 10.1111/bjh.12661.
Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol. 2008; 142(3):427-35. DOI: 10.1111/j.1365-2141.2008.07182.x.
Afable MG 2nd, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011; 96(9):1269-75. DOI: 10.3324/haematol.2011.042622.
Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006; 107(4):1308-14. DOI: 10.1182/blood-2005-06-2485.
Wang H, Chuhjo T, Yamazaki H, Shiobara S, Teramura M, Mizoguchi H, et al. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001; 66(3):200-5. DOI: 10.1034/j.1600-0609.2001.00376.x.
Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol. 2001; 115(4):1015-22. DOI: 10.1046/j.1365-2141.2001.03191.x.
Mather KA, Jorm AF, Parslow RA, Christensen H. Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci. 2011; 66(2):202-13. DOI: 10.1093/gerona/glq180
Brümmendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001; 97(4):895-900. DOI: 10.1182/blood.v97.4.895.
Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010; 304(12):1358-64. DOI: 10.1001/jama.2010.1376.
Sakaguchi H, Nishio N, Hama A, Kawashima N, Wang X, Narita A, et al. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2014; 99(8):1312-6. DOI: 10.3324/haematol.2013.091165.
Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011; 365(5):430-8. DOI: 10.1056/NEJMoa1103975.
Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995; 85(5):1348-53.
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357(22):2237-47. DOI: 10.1056/NEJMoa073275.
Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol. 2008; 140(2):197-205. DOI: 10.1111/j.1365-2141.2007.06903.x.
Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011; 117(17):4434-41. DOI: 10.1182/blood-2010-08-304071.
Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009; 94(5):712-9. DOI: 10.3324/haematol.2008.002170.
Viollier R, Passweg J, Gregor M, Favre G, Kühne T, Nissen C, et al. Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol. 2005; 84(1):47-55. DOI: 10.1007/s00277-004-0930-3.
Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999; 107(2):330-4. DOI: 10.1046/j.1365-2141.
Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436. DOI: 10.1182/blood-2016-08-693481.
Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009; 27(2):424-30. DOI: 10.1634/stemcells.2008-0366.
Groarke EM, Patel BA, Gutierrez-Rodrigues F, Rios O, Lotter J, Baldoni D, et al. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia. Br J Haematol. 2021; 192(3):605-614. DOI: 10.1111/bjh.17232..
Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111(3):981-6. DOI: 10.1182/blood-2007-05-088500.
Zeigler FC, de Sauvage F, Widmer HR, Keller GA, Donahue C, Schreiber RD, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994; 84(12):4045-52.
Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014; 99(12):1784-91. DOI: 10.3324/haematol.2014.109355.
Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006; 34(7):826-31. DOI: 10.1016/j.exphem.2006.03.017
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Miguel Angel Castaño-Morales
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
